These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8595575)

  • 1. Interpreting results from thrombolytic megatrials: distinguishing fact from fiction.
    Brophy JM
    Can J Cardiol; 1996 Jan; 12(1):89-92. PubMed ID: 8595575
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
    Califf RM; Stump D; Topol EJ; Mark DB
    Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606
    [No Abstract]   [Full Text] [Related]  

  • 3. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
    Boland A; Dundar Y; Bagust A; Haycox A; Hill R; Mujica Mota R; Walley T; Dickson R
    Health Technol Assess; 2003; 7(15):1-136. PubMed ID: 12773258
    [No Abstract]   [Full Text] [Related]  

  • 5. Emergent decision-making: defining the patient perspective.
    Knudtson ML
    Can J Cardiol; 2005 Apr; 21(5):433-4. PubMed ID: 15861261
    [No Abstract]   [Full Text] [Related]  

  • 6. From thrombolytic megatrials to clinical policy-making: facing the facts.
    Naylor CD; Armstrong PW
    Can J Cardiol; 1995 Jun; 11(6):472-6. PubMed ID: 7780867
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W; Pierre K; Massel D
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
    Coyle D; Buxton MJ; O'Brien BJ
    Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials: the pitfalls of interpretation.
    Lokhandwalla Y; Dalvi B
    Issues Med Ethics; 1998 Apr; 6(2):47-8. PubMed ID: 15011700
    [No Abstract]   [Full Text] [Related]  

  • 11. Emergency physician survey: recombinant tissue plasminogen activator for stroke.
    Mann J
    Ann Emerg Med; 2006 Oct; 48(4):476; author reply 477. PubMed ID: 16997689
    [No Abstract]   [Full Text] [Related]  

  • 12. Bayesian cost-effectiveness analysis. An example using the GUSTO trial.
    Fryback DG; Chinnis JO; Ulvila JW
    Int J Technol Assess Health Care; 2001; 17(1):83-97. PubMed ID: 11329847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validity of the GUSTO trial's main conclusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronaries.
    Eisenberg C
    Pharmacotherapy; 1997; 17(4):850-2. PubMed ID: 9250573
    [No Abstract]   [Full Text] [Related]  

  • 14. [Fibrinolytic therapy of patients with pulmonary artery thromboembolism by tissue plasminogen activator and streptokinase preparations].
    Ardashev VN; Sokolianskiĭ NV; Bystrov VV
    Klin Med (Mosk); 2000; 78(12):28-30. PubMed ID: 11210347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolysis for acute myocardial infarction: drug review.
    Cundiff DK
    MedGenMed; 2002 Jan; 4(1):1. PubMed ID: 11965203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombolytic treatment of acute myocardial infarct. 1].
    Soares-Costa JT; Soares-Costa TJ; Gabriel HM
    Acta Med Port; 1998 May; 11(5):409-19. PubMed ID: 9951051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue plasminogen activator as an adjuvant therapy for pleural empyema in pediatric patients.
    Ray TL; Berkenbosch JW; Russo P; Tobias JD
    J Intensive Care Med; 2004; 19(1):44-50. PubMed ID: 15035754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism.
    Perlroth DJ; Sanders GD; Gould MK
    Arch Intern Med; 2007 Jan; 167(1):74-80. PubMed ID: 17210881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic therapy in patients with acute ischemic stroke.
    Hinchey JA; Benesch C
    Arch Neurol; 2000 Oct; 57(10):1430-6. PubMed ID: 11030794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.